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Abstract
Background: Parathyroid adenoma is the most common cause of primary hyperparathyroidism.
Preoperative serum calcium and intact-parathyroid hormone levels are the most useful diagnostic
parameters that allow differentiating primary hyperparathyroidism from non-parathyroid-
dependent hypercalcemia. Parathyroidectomy is the definitive treatment for primary
hyperparathyroidism. Approximately 5% of patients who underwent parathyroidectomy present
with persistent or recurrent hyperparathyroidism due to ectopic localization of the adenoma.
Functioning oxyphil parathyroid adenoma is an uncommon histological form, seldom causing
primary hyperparathyroidism. Parathyroid adenoma with hypercalcemia exhibiting normal
parathyroid hormone level is rare. An incidence of 5% to 33% has been documented in the
literature; no etiologic explanation has been given. In 1987, parathyroid-hormone-related peptide
was isolated as a causative factor of humeral hypercalcemia of malignancy. The presence of
parathyroid-hormone-related peptide in parathyroid tissue under normal and pathological
conditions has been described in the literature; however, its role in causing hyperparathyroidism
has not yet been defined.
Case presentation: We present a case of persistent hypercalcemia with a normal level of intact-
parathyroid hormone due to a substernal parathyroid adenoma, treated with radioguided
parathyroidectomy. The final histological diagnosis was oxyphil adenoma, positive for parathyroid-
hormone-related peptide antigens.
Conclusion:  In clinical practice, this atypical biochemical presentation of primary
hyperparathyroidism should be considered in the differential diagnosis of hypercalcemia. The
parathyroid-hormone-related peptide should be considered not only in the presence of malignancy.
Background
The diagnosis of primary hyperparathyroidism (PHPT) is
based on hypercalcemia and elevated levels of parathy-
roid hormone (PTH); additional laboratory hallmark fea-
tures are hypophosphatemia and elevated urinary cyclic
adenosine monophosphate (cAMP). The advent of intact-
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PTH immunoradiometric assay has further increased the
reliability of results, enabling to distinguish PHPT from
non-parathyroid-dependent hypercalcemia.
Eighty to 85% of patients with PHPT have a single parath-
yroid adenoma [1] that is ectopic in 5% to 10% of cases
[2]. Ectopic parathyroid adenoma is a frequent cause of
surgical failure and, therefore, several authors recommend
preoperative imaging to localise the condition in patients
with PHPT before initiating surgery. Thus, about 5% of
patients who underwent parathyroidectomy present per-
sistent or recurrent hyperparathyroidism [3].
Predominantly composed of chief cells, parathyroid ade-
nomas are the most frequent cause of PHPT. Uncom-
monly, PHPT is caused by oxyphil adenoma, an
infrequent histological form considered exclusively non-
functioning until 1970 [4]. These adenomas consist of
cells with abundant eosinophilic cytoplasm that corre-
lates ultrastructurally with numerous mitochondria.
Presentation of hypercalcemia and normal PTH level due
to parathyroid adenoma is infrequent; however, its inci-
dence has been estimated to be between 5% and 33% [5].
In 1987, parathyroid-hormone-related peptid (PTHrP)
has been isolated as a causative factor of humoral hyper-
calcemia of malignancy (HHM). The presence of PTHrP in
parathyroid tissue has been described in the literature;
however, its role in causing hyperparathyroidism has not
yet been defined [6].
We present a case of persistent hypercalcemia with a nor-
mal level of intact-PTH due to a substernal oxyphil parath-
yroid adenoma positive for PTHrP, treated by radioguided
parathyroidectomy.
Case presentation
A 30-year-old man was referred to our Department of
General Surgery for evaluation of persistent hypercal-
cemia. History revealed a 10-year history of constipation,
recurrent episodes of renal colic, chronic fatigue, dyspep-
sia and hypercalcemia of unknown etiology. Eight
months prior, in a different hospital, the patient under-
went neck ultrasound that revealed a hypoechogenic mass
located under the left thyroid lobe with an intense uptake
during Tc-99m-sestamibi parathyroid scintigraphy. Sub-
sequent surgical neck exploration had been unsuccessful.
Endocrinologic family history was uneventful; the
patient's parents and two brothers had normal serum cal-
cium levels and his one child was healthy. He did not take
vitamin supplements, lithium or thiazide diuretics. Phys-
ical examination was negative, motor strength and
reflexes were normal. Renal scan showed bilateral nephro-
lithiasis, and orthopantomography revealed signs of bone
resorption at the jaw level.
Laboratory tests on admission showed hypercalcemia
(12.7 mg/dL), hypophosphatemia (0.90 mg/dL), normal
intact-PTH level (41.0 pg/mL) and an increase in 1,25-
dihydroxycholecalciferol level (148.7 pg/mL). Urine bio-
chemistry revealed elevated 24-hour urine calcium excre-
tion (559 mg/24 h), phosphate clearance (57.8 mL/min)
and urinary calcium to creatinine clearance 2 hours (0.30
mg/mg creatinine), whereas urinary cAMP was normal
(3.9 nmol/100 mL glomerular filtrate). Thyroid and kid-
ney function tests were within normal limits; tumor mark-
ers and blood tests for metabolic abnormalities were
negative.
Neck ultrasound was not significant; thorax CT scan
revealed an encapsulated mass of 3 cm in the upper ante-
rior mediastinum located behind the sternoclavicular
junction (Figure 1). Tc-99m sodium pertechnetate/Tc-
99m-sestamibi parathyroid dual-phase scintigraphy with
subtraction image technique revealed the mass to be an
ectopic parathyroid adenoma at the level of the left ster-
noclavicular junction (Figure 2).
Multislice CT revealed an encapsulated mass of 3 cm in the  upper anterior mediastinum behind the sternum-clavicular  joints, with marked peripheral enhancement (arrow) Figure 1
Multislice CT revealed an encapsulated mass of 3 cm 
in the upper anterior mediastinum behind the ster-
num-clavicular joints, with marked peripheral 
enhancement (arrow).World Journal of Surgical Oncology 2008, 6:24 http://www.wjso.com/content/6/1/24
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These data confirmed the hypothesis of parathyroid-
dependent hypercalcemia. A radioguided adenoma resec-
tion through a collar reincision was performed. One hour
prior to surgery, 50 MBq of Tc-99m – sestamibi was
injected intravenously; in the operating room, the gamma
probe (MR-100, 11C, Pol.hi.tech) was used to identify the
following: in vivo localization of the cutaneous projection
of the adenoma; ex vivo uptake of the 3.2 cm excised
ectopic adenoma and, lastly, to confirm removal of the
pathologic gland, on the "background" operated area. A
biopsy of the right inferior parathyroid, though appar-
ently normal, was performed. Intraoperative PTH was
reduced by more than 50% compared to the normal pre-
operative level.
Histologically, the tumor consisted of cords and small
nests of cells with large granular eosinophilic cytoplasm
with round to oval nuclei; the final diagnosis was oxyphil
adenoma. Tumor cells were immunohistochemically pos-
itive for PTH (DakoCytomation; dilution 1:100; mouse)
and PTHrP (Acris; 1:200; rabbit) antigens (Figure 3). The
gland biopsy was normal.
Serum calcium level was normal in the immediate post-
operative period (8.9 mg/dL) and 1, 6 and 12 months
after surgery (8.6-8.9-8.4 mg/dL, respectively), with
unchanged PTH within normal limits (11 pg/mL, day 1
after surgery; 9.4-13.0-17.0 pg/mL in 1, 6 and 12 months
after surgery, respectively).
Recovery was uneventful and the patient was discharged
24 hours after the operation.
Discussion
Hypercalcemia is one of the most common metabolic dis-
orders and it may be generated by many different patho-
logic conditions. The most common categories are
malignancy, PHPT and vitamin D-induced hypercal-
cemia; the less frequent include drug-induced conditions
(eg, lithium, thiazide diuretics), immobilization, tubercu-
losis, sarcoidosis and rhabdomyolysis.
Identifying disease etiology is very important, since, sub-
sequent management differs according to pathology.
Although a detailed personal and family history, physical
examination, and laboratory analyses can differentiate the
causes in most cases, hypercalcemia often remains a chal-
lenging condition for clinicians. PTH level is the classic
discriminator between parathyroid disease-dependent
hypercalcemia and others, whereas PTHrP is the most use-
ful analytical method in HHM.
The most frequent cause of PHPT is a solitary adenoma
composed mainly of chief cells producing PTH. In con-
trast, oxyphil adenoma meets the following criteria: 1)
consists of at least 90% oxyphil cells; 2) histologically nor-
mal excision or biopsy of a second gland excluding the
possibility of parathyroid hyperplasia; and 3) immediate
postoperative normalization of hypercalcemia [7]. In this
reported case, all the criteria were met.
Strong and diffuse expression of PTHrP in the oxyphil ade- noma (200 × original magnification) Figure 3
Strong and diffuse expression of PTHrP in the oxyphil ade-
noma (200 × original magnification).
Tc-99m-sestamibi Tc-99m sodium pertechnetate substrac- tion image showed an area of intense uptake below the infe- rior pole of the left thyroid lobe, in the upper mediastinum,  in the left median position and normal thyroid with homoge- nous radiopharmaceutical uptake (arrow) Figure 2
Tc-99m-sestamibi Tc-99m sodium pertechnetate 
substraction image showed an area of intense uptake 
below the inferior pole of the left thyroid lobe, in the 
upper mediastinum, in the left median position and 
normal thyroid with homogenous radiopharmaceuti-
cal uptake (arrow).World Journal of Surgical Oncology 2008, 6:24 http://www.wjso.com/content/6/1/24
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The literature review reports 142 cases of oxyphil parathy-
roid adenomas [8-10]. The ability of this histological form
to secrete PTH has been demonstrated during the last 30
years [11] ; in fact, hypercalcemia was associated to secre-
tion of PTH due to oxyphil adenomas in only 124 of 142
reported cases [8,10,11].
Since 1976, approximately 140 cases of hypercalcemia
and normal PTH levels due to parathyroid adenoma have
been reported in the literature [12-15] ; however, no cor-
relation between the atypical biochemical presentation,
histological features and causative factors has been dem-
onstrated. In this regard, Hollemberg et al. [14] and Perez
et al. [13] proposed the following theoretical explanations
to the mechanism of inappropriately low PTH level in the
PHPT cases observed: a circulating inhibitor of PTH; the
pulsatile secretion of the hormone; an abnormal PTH
molecule with increased biologic activity; increased
peripheral tissue sensitivity to normal PTH; or the pres-
ence of another mediator of hypercalcemia (eg, PTHrP).
None of these hypotheses have been verified. Lafferty et al.
[12] emphasized that PHPT cannot always be ruled out
because of a low-normal serum intact or biointact PTH
and suggested that repeated PTH measurements after
serum dilution in suspected cases of PHPT with low-nor-
mal PTH levels may be a useful method for detecting atyp-
ical forms of PTH.
PTHrP is a factor responsible for malignancies associated
with hypercalcemia such as lung cancer, breast carcinoma,
pancreatic endocrine tumors, renal cell carcinoma;
esophageal squamosous cell carcinoma, pheochromocy-
toma and hematological neoplasia. PTHrP has been dem-
onstrated in adult human parathyroid tissue under
normal and pathological conditions; however, the role of
this peptid secreted in 12 reported cases of oxyphil parath-
yroid adenoma associated with hypercalcemia has not yet
been defined [9,10]. In fact, in 11 cases, the PTH level has
not been reported [9], and in one, hypercalcemia
depended on simultaneous hypersecretion of PTH [10].
Nevertheless, these studies have established the correla-
tion of PTHrP expression with the age-related metaplastic
change of parathyroid cells into the oxyphil phenotype,
through a paracrine/autocrine regulatory mechanism
[9,10].
To our knowledge, the association of immunohistochem-
ical positivity for PTHrP-antigens with normal PTH levels,
the immediate postoperative normalization of hypercal-
cemia, and the histological features of parathyroid ade-
noma have not been previously reported.
Moreover, technetium Tc-99m sestamibi imaging tech-
niques have played a very important role in defining the
preoperative localization in this case study. The predomi-
nance of oxyphil cells within an adenoma actually
increases Tc-99m-sestamibi scan sensitivity in a statisti-
cally significant manner, since sestamibi uptake likely
increases in more metabolically active lesions and when
the preoperative calcium level is ≥ 9.5 mg/dL so as to
reduce the risks of bilateral surgical neck exploration and
persistent PHPT [8].
Conclusion
In light of the reported data, PTHrP plays a critical role in
defining the pathogenesis of atypical hypercalcemia due
to parathyroid adenoma without hypersecretion of PTH.
In clinical practice, this biochemical presentation should
be considered in the differential diagnosis of hypercal-
cemia, and serum PTHrP should be assessed not only in
the presence of malignancy. Additional studies with larger
populations are necessary to associate the various clinical
and biochemical presentations of PHPT with preoperative
diagnostic flow-charts.
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